2025-04-04 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis

**0. Executive Summary:**

Intuitive Surgical Inc. (ISRG) is a leading medical device company focused on robotic-assisted surgery.  This report analyzes ISRG's performance relative to the S&P 500 (VOO), recent price movements, key financial indicators, and recent earnings.

**1. Performance vs. S&P 500:**

ISRG has significantly outperformed the S&P 500.  The cumulative return of ISRG is 212.45%, while the S&P 500's cumulative return is 85.44%. This represents a difference of 127.0 percentage points. The relative divergence (based on historical min/max range) indicates ISRG is at the 78.7th percentile compared to the S&P 500, suggesting a strong historical outperformance.

Alpha and Beta analysis shows varying results across different time periods. While some periods demonstrate positive alpha (outperformance relative to market risk), others show negative alpha.  Beta values are consistently high, indicating higher volatility than the market.  The company's market capitalization has grown significantly over the analyzed period.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 66.0% | 10.1% | -0.1 | 43.6 |
| 2016-2018  | 77.0% | 49.6% | -0.1 | 57.2 |
| 2017-2019  | 82.0% | 49.6% | 0.2 | 70.6 |
| 2018-2020  | 53.0% | 49.6% | 0.3 | 97.7 |
| 2019-2021  | 100.0% | 18.4% | 0.3 | 128.7 |
| 2020-2022  | 17.0% | 53.7% | 0.3 | 95.1 |
| 2021-2023  | 19.0% | 55.0% | 0.9 | 120.9 |
| 2022-2024  | 103.0% | 55.0% | 0.9 | 187.0 |
| 2023-2025  | 123.0% | 55.0% | 0.8 | 177.2 |


**2. Recent Price Movements:**

* **Closing Price:** $494.61
* **Previous Close:** $507.05
* **Change:** -$2.45 (a decrease of 0.48%)
* **5-day Moving Average:** $497.03
* **20-day Moving Average:** $496.63
* **60-day Moving Average:** $551.29

The price is currently below all three moving averages, suggesting a potential short-term bearish trend.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.432 (Low Risk)  This suggests relatively low market risk currently.
* **RSI:** 55.03 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.51 (Positive, suggesting bullish momentum)
* **20-day Relative Divergence Change:** -2.5% (Short-term downtrend)
* **Expected Return:** 26.2% (over S&P 500 over 2+ years)


The recent price drop of $2.45 suggests a moderate bearish correction, but the overall picture is mixed.

**4. Recent Earnings Analysis:**

The provided earnings data shows relatively consistent revenue growth, although EPS fluctuates slightly.  There appears to be no major concerning trends.  Further analysis would benefit from comparing these figures to previous years' data and industry benchmarks.

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2024-10-18 | 1.59 | $2.04 B     |
| 2024-07-19 | 1.48 | $2.01 B     |
| 2024-04-19 | 1.54 | $1.89 B     |
| 2023-10-20 | 1.18 | $1.74 B     |
| 2024-10-18 | 1.18 | $1.74 B     |  *(Likely a duplicate entry)*


**5. Financial Information:**

Both revenue and profitability (profit margin) show a generally positive trend.  Equity is also increasing, though ROE fluctuates.  Further analysis is needed to assess the sustainability of these trends.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |


**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |
| 2024-03-31 | $13.96B | 3.90% |
| 2023-12-31 | $13.31B | 4.56% |


**6. Overall Conclusion:**

ISRG has demonstrated strong historical outperformance compared to the S&P 500.  While recent price action shows a short-term decline, the company's financial health appears sound, with consistent revenue growth and high profit margins.  The high beta indicates significant volatility, which should be considered.  The projected long-term expected return is significant, but this should be viewed in conjunction with the inherent risks associated with investing in a high-growth, high-volatility stock. Further due diligence, including a deeper analysis of the competitive landscape and future growth prospects, is recommended before making any investment decisions.  Note that this analysis is based on limited data and should not be considered financial advice.
